Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial

Lack of effective targeted therapy in metastatic esophageal squamous cell carcinoma (ESCC) underscores the urgent need for identifying new treatment approaches for this challenging disease. We sought to assess the addition of cetuximab to paclitaxel-cisplatin chemotherapy for first-line treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Zhihao, Zhang, Yanqiao, Fan, Qingxia, Pan, Yueyin, Jiang, Da, Lu, Ping, Zhang, Jingdong, Yuan, Xianglin, Feng, Jifeng, Yang, Shujun, Yue, Wenbin, Zhao, Lin, Xu, Yunhua, Luo, Jinhua, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059084/
https://www.ncbi.nlm.nih.gov/pubmed/35509869
http://dx.doi.org/10.1016/j.xinn.2022.100239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059084/
https://www.ncbi.nlm.nih.gov/pubmed/35509869
http://dx.doi.org/10.1016/j.xinn.2022.100239

Ejemplares similares